Publication: EXENATIDE-PD3

4 February 2025

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

The Exenatide-PD3 trial team have published a paper via the Lancet Journal, which is available to read on their website here.